Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Sleep Cycle AB in connection with the listing on Nasdaq Stockholm
Mandate

Vinge advises Sleep Cycle AB (publ) in connection with the listing on Nasdaq Stockholm

June 08, 2021 Capital Markets and Public M&A M&A Corporate Tax Intellectual Property Employment and Benefits

Vinge advises Sleep Cycle AB (publ) (“Sleep Cycle” or the “Company”) in connection with the listing on Nasdaq Stockholm. The offering circular was published on 28 May 2021 and the first day of trading on Nasdaq Stockholm was 8 June 2021.

The offering price was SEK 70 per share, corresponding to a market value of Sleep Cycle of approximately SEK 1.3bn. The offering comprised 4,870,171 shares, of which 1,428,571 are newly issued shares and 3,441,600 are existing shares.

Sleep Cycle is a market leading sleep tracking application with a mission to empower people to sleep better to improve global health. Sleep Cycle uses a patented AI-based audio technology to measure users’ sleep and provide personalized insights based on the Company’s sleep database. Sleep Cycle was founded in 2009 and is headquartered in Gothenburg, Sweden.

Vinge’s team mainly consisted of Jesper Schönbeck, Linnéa Sellström, Joel Magnusson and Lorin Arabi (Capital Markets and Public M&A), Matthias Pannier, Vilhelm Rondahl and Mikaela Falkner (M&A), Victor Ericsson, Henrik Wastenson and Jonathan Riddersholm (Corporate tax), Stojan Arnestål and Felizia Wiker (IP) and Ebba Svenburg (Employment and Benefits).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025